Published in J Pain Symptom Manage on March 01, 2006
Endogenous opiates and behavior: 2006. Peptides (2007) 0.92
Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey. Support Care Cancer (2008) 0.86
The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. Korean J Intern Med (2014) 0.78
Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Ther Clin Risk Manag (2015) 0.75
The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids. Support Care Cancer (2016) 0.75
[Limits of pain treatment: medical and judicial aspects]. Schmerz (2011) 0.75
Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res (2007) 3.22
Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol (2004) 1.95
Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood (2003) 1.65
High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer (2011) 1.65
Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases. N Z Med J (2003) 1.47
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev (2010) 1.45
CT-guided neurolytic splanchnic nerve block by an anterior approach. J Pain Symptom Manage (2002) 1.39
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol (2009) 1.27
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev (2010) 1.15
Physical exercise and quality of life in breast cancer survivors. Int J Med Sci (2008) 1.14
Management of painful bone metastases. Curr Opin Oncol (2007) 1.12
Palliative sedation in patients with advanced cancer followed at home: a systematic review. J Pain Symptom Manage (2011) 1.06
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain (2008) 1.04
Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol (2002) 1.01
Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage (2009) 1.00
Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage (2004) 0.99
Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer (2004) 0.98
Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage (2004) 0.97
Peritoneal catheter for continuous drainage of ascites in advanced cancer patients. Support Care Cancer (2008) 0.97
Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage (2005) 0.96
The use of high doses of oxycodone in an acute palliative care unit. Am J Hosp Palliat Care (2010) 0.96
High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients. J Pain Symptom Manage (2008) 0.96
A model of acute symptom control unit: Pain Relief and Palliative Care Unit of La Maddalena Cancer Center. Support Care Cancer (2002) 0.96
Opioid escalation in patients with cancer pain: the effect of age. J Pain Symptom Manage (2006) 0.95
Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain (2007) 0.93
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res (2008) 0.93
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin Cancer Res (2006) 0.93
Opioids and renal function. J Pain (2004) 0.93
The Supportive Care Task Force at the University of L'Aquila: 2-years experience. Support Care Cancer (2005) 0.92
Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Med Oncol (2008) 0.92
Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience. Clin Neuropharmacol (2010) 0.92
Controlled sedation for refractory symptoms in dying patients. J Pain Symptom Manage (2008) 0.91
Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage (2003) 0.91
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. Clin Colorectal Cancer (2011) 0.91
In vivo bone metastases, osteoclastogenic ability, and phenotypic characterization of human breast cancer cells. Bone (2004) 0.91
Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin (2012) 0.91
Can malignant bowel obstruction in advanced cancer patients be treated at home? Support Care Cancer (2010) 0.91
Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation. Oncology (2002) 0.90
The palliative prognostic score and survival in patients with advanced solid tumors receiving chemotherapy. Support Care Cancer (2007) 0.90
Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line. Anticancer Res (2004) 0.90
Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage (2004) 0.90
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer (2010) 0.90
Patients' and relatives' perceptions about intravenous and subcutaneous hydration. J Pain Symptom Manage (2005) 0.89
The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology (2010) 0.89
Efficacy and safety of deep, continuous palliative sedation at home: a retrospective, single-institution study. Support Care Cancer (2009) 0.89
Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. J Cancer Res Clin Oncol (2011) 0.88
Long-term central venous catheterization via persistent left superior vena cava: a case report. Support Care Cancer (2003) 0.88
Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage (2006) 0.87
Serum follistatin in patients with prostate cancer metastatic to the bone. Clin Exp Metastasis (2010) 0.87
Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. Prostate (2009) 0.87
Opioid-induced or pain relief-reduced symptoms in advanced cancer patients? Eur J Pain (2006) 0.87
Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer (2002) 0.87
Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin (2013) 0.87
Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin (2012) 0.86
How do cancer patients receiving palliative care at home die? A descriptive study. J Pain Symptom Manage (2011) 0.86
Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. J Pain Symptom Manage (2007) 0.86